Approaching coherent performance in differential detection via diversity von Magen, Adam, Amrani, Ofer

Volltext

REAL-TIME MORPHOLOGY ANALYSIS FOR LESION ASSESSMENT von STEWART, Brian, BENNETT, Nathan H, HULTZ, Paul, MAGEN, Adam, WEISMAN, Michal

Volltext bestellen

Real-time morphology analysis for lesion assessment von Magen Adam, Stewart Brian, Weisman Michal, Bennett Nathan H, Hultz Paul

Volltext bestellen

REAL-TIME MORPHOLOGY ANALYSIS FOR LESION ASSESSMENT von STEWART, BRIAN, WEISMAN, MICHAL, BENNETT, NATHAN H, HULTZ, PAUL, MAGEN, ADAM

Volltext bestellen

REAL-TIME MORPHOLOGY ANALYSIS FOR LESION ASSESSMENT von STEWART BRIAN, HULTZ PAUL, WEISMAN MICHAL, MAGEN ADAM, BENNETT NATHAN H

Volltext bestellen

Real-time morphology analysis for lesion assessment von STEWART BRIAN, HULTZ PAUL, WEISMAN MICHAL, MAGEN ADAM, BENNETT NATHAN H

Volltext bestellen

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1 von Garrelfs, Sander F, Frishberg, Yaacov, Hulton, Sally A, Koren, Michael J, O’Riordan, William D, Cochat, Pierre, Deschênes, Georges, Shasha-Lavsky, Hadas, Saland, Jeffrey M, van’t Hoff, William G, Fuster, Daniel G, Magen, Daniella, Moochhala, Shabbir H, Schalk, Gesa, Simkova, Eva, Groothoff, Jaap W, Sas, David J, Meliambro, Kristin A, Lu, Jiandong, Sweetser, Marianne T, Garg, Pushkal P, Vaishnaw, Akshay K, Gansner, John M, McGregor, Tracy L, Lieske, John C

Volltext

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma von Lonial, Sagar, Dimopoulos, Meletios, Palumbo, Antonio, White, Darrell, Grosicki, Sebastian, Spicka, Ivan, Walter-Croneck, Adam, Moreau, Philippe, Mateos, Maria-Victoria, Magen, Hila, Belch, Andrew, Reece, Donna, Beksac, Meral, Spencer, Andrew, Oakervee, Heather, Orlowski, Robert Z, Taniwaki, Masafumi, Röllig, Christoph, Einsele, Hermann, Wu, Ka Lung, Singhal, Anil, San-Miguel, Jesus, Matsumoto, Morio, Katz, Jessica, Bleickardt, Eric, Poulart, Valerie, Anderson, Kenneth C, Richardson, Paul

Volltext

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study von Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Weisel, Katja, San-Miguel, Jesus, Shpilberg, Ofer, Grosicki, Sebastian, Špička, Ivan, Walter-Croneck, Adam, Magen, Hila, Mateos, Maria-Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Spencer, Andrew, Oakervee, Heather, Orlowski, Robert Z., Taniwaki, Masafumi, Röllig, Christoph, Einsele, Hermann, Matsumoto, Morio, Wu, Ka Lung, Anderson, Kenneth C., Jou, Ying-Ming, Ganetsky, Alex, Singhal, Anil K., Richardson, Paul G.

Volltext

TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer von Park, Matthew D., Reyes-Torres, Ivan, LeBerichel, Jessica, Hamon, Pauline, LaMarche, Nelson M., Hegde, Samarth, Belabed, Meriem, Troncoso, Leanna, Grout, John A., Magen, Assaf, Humblin, Etienne, Nair, Achuth, Molgora, Martina, Hou, Jinchao, Newman, Jenna H., Farkas, Adam M., Leader, Andrew M., Dawson, Travis, D’Souza, Darwin, Hamel, Steven, Sanchez-Paulete, Alfonso Rodriguez, Maier, Barbara, Bhardwaj, Nina, Martin, Jerome C., Kamphorst, Alice O., Kenigsberg, Ephraim, Casanova-Acebes, Maria, Horowitz, Amir, Brown, Brian D., De Andrade, Lucas Ferrari, Colonna, Marco, Marron, Thomas U., Merad, Miriam

Volltext

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth... von Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Palumbo, Antonio, San‐Miguel, Jesus, Shpilberg, Ofer, Anderson, Kenneth, Grosicki, Sebastian, Spicka, Ivan, Walter‐Croneck, Adam, Magen, Hila, Mateos, Maria‐Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Bleickardt, Eric, Poulart, Valerie, Sheng, Jennifer, Sy, Oumar, Katz, Jessica, Singhal, Anil, Richardson, Paul

Volltext

Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM) von Lonial, Sagar, Dimopoulos, Meletios A., Weisel, Katja, White, Darrell, Moreau, Philippe, Mateos, Maria-Victoria, San-Miguel, Jesus, Anderson, Kenneth Carl, Shpilberg, Ofer, Grosicki, Sebastian, Spicka, Ivan, Walter-Croneck, Adam, Magen, Hila, Belch, Andrew, Reece, Donna Ellen, Beksac, Meral, Shelat, Suresh, Sy, Oumar, Singhal, Anil K., Richardson, Paul G.

Volltext

ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple my... von Lonial, Sagar, Dimopoulos, Meletios A., Palumbo, Antonio, White, Darrell, Grosicki, Sebastian, Spicka, Ivan, Walter-Croneck, Adam, Moreau, Philippe, Mateos, María-Victoria, Magen-Nativ, Hila, Belch, Andrew, Reece, Donna Ellen, Beksac, Meral, Taniwaki, Masafumi, Röllig, Christoph, Singhal, Anil K., Katz, Jessica, Bleickardt, Eric W., Poulart, Valerie, Richardson, Paul G.

Volltext

Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM) von Lonial, Sagar, Dimopoulos, Meletios A., Weisel, Katja C., White, Darrell, Moreau, Philippe, Mateos, Maria-Victoria, San Miguel, Jesus, Anderson, Kenneth Carl, Shpilberg, Ofer, Grosicki, Sebastian, Spicka, Ivan, Walter-Croneck, Adam, Magen, Hila, Belch, Andrew, Reece, Donna Ellen, Beksac, Meral, Mekan, Sabeen, Sy, Oumar, Singhal, Anil K., Richardson, Paul G.

Volltext

Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial von Dimopoulos, Meletios A., Weisel, Katja, Lonial, Sagar, White, Darrell, Moreau, Philippe, Mateos, Maria-Victoria, San-Miguel, Jesus, Anderson, Kenneth C., Shpilberg, Ofer, Grosicki, Sebastian, Spicka, Ivan, Walter-Croneck, Adam, Magen, Hila, Belch, Andrew, Reece, Donna, Beksac, Meral, Ganetsky, Alex, Jou, Ying-Ming, McKiver, Mihaela Popa, Singhal, Anil K., Richardson, Paul G.

Volltext

Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Ye... von Dimopoulos, Meletios A., Lonial, Sagar, White, Darrell, Moreau, Philippe, Palumbo, Antonio, San Miguel, Jesus, Shpilberg, Ofer, Anderson, Kenneth C., Grosicki, Sebastian, Spicka, Ivan, Walter-Croneck, Adam, Magen-Nativ, Hila, Mateos, Maria-Victoria, Belch, Andrew, Reece, Donna, Beksac, Meral, Bleickhardt, Eric, Poulart, Valerie, Katz, Jessica, Singhal, Anil K., Richardson, Paul G.

Volltext

Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM) von Lonial, Sagar, Dimopoulos, Meletios, Weisel, Katja, White, Darrell, Moreau, Philippe, Mateos, Maria-Victoria, San Miguel, Jesus, Anderson, Kenneth, Shpilberg, Ofer, Grosicki, Sebastian, Spicka, Ivan, Walter-Croneck, Adam, Magen, Hila, Belch, Andrew, Reece, Donna, Beksac, Meral, Shelat, Suresh, Sy, Oumar, Singhal, Anil, Richardson, Paul

Volltext

Editorial Leadership of Academic Psychiatry von Roberts, Laura Weiss

Volltext

AN INTERACTIVE COMPUTERIZED MECHANICAL-TESTING MEASUREMENT SYSTEM von Adam, G., Rosenthal, Y., Mark-Markowitch, M., Frenkel, R., Cohen, P., Magen, A.

Volltext

DISPUTATIO INAUGURALIS, De CAMBIALIUM LITERARUM ACCEPTATIONE, Von Acceptirung dr Wechsel-Brieffe von Johann Ehrenfried Martini, Johann Joachim Schoepffer, Georg Wilhelm Koepke, Johann Bernhard Friese, jo20191059050

Volltext bestellen